The nation of Zimbabwe has rejected a substantial American healthcare agreement valued at $367m (272 million pounds) spanning five years because of Washington's demand for confidential information.
This rejection became public after a official document from December was leaked, indicating that President Emmerson Mnangagwa felt the arrangement was "lopsided".
A government spokesperson later clarified that the US was requesting health data for research and profit but was unwilling to guarantee the benefits from any future medical innovations.
"We must now begin the difficult and regrettable process of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for further negotiations to find a deal suitable to all parties so the nation's critical HIV treatment initiative can proceed.
Wider Background
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a high court suspended a related deal with the US following concerns were filed about the security of Kenyans' medical information.
Since resuming the presidency recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump stated its spending was "inefficient" and his government was seeking direct bilateral agreements to boost openness and accountability.
According to statements, Sixteen nations in Africa have so far agreed to these new agreements, constituting over $18.3bn in committed funds.
Details of the Rejected Deal
The money for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation could have provided immense advantages for the people of Zimbabwe, especially the 1.2 million presently receiving antiretroviral therapy through US-supported initiatives," Tremont added.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, without any corresponding assurance of access to any medical innovations – like new medicines or tests – that might be developed from that provided information," he stated.
"Put simply, our country would provide the basic resources for medical research with no certainty that the resulting innovations would be accessible to our citizens should a future disease outbreak arise."
Sovereignty and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were undermining frameworks already set up through the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to deal with potential pandemics.
"This mechanism is intended to ensure that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage ongoing discussions with our US partners on how future co-operation might be arranged in a manner that respects the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body said it understood the official position, but suggested that talks should continue given that much of the nation's HIV programmes depended on external financing.
"In cases where technical issues exist, such as those relating to information security or implementation frameworks, these can frequently be addressed through technical clarification and negotiated safeguards," the group said.
The situation emphasises the continuing debate between accepting much-needed foreign assistance and protecting a country's data in an ever more data-driven world.